FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme (Q37629395)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme |
scientific article |
Statements
1 reference
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme (English)
1 reference
Martin H Cohen
1 reference
Yuan Li Shen
1 reference
Patricia Keegan
1 reference
Richard Pazdur
1 reference
6 November 2009
1 reference
Identifiers
1 reference